{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-323628","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2026-07-29T20:03:42+00:00","discovered_at":"2026-07-29T20:05:00.776690+00:00","generated_at":"2026-07-29T20:05:20.328318+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inovio reports preliminary Q2 2026 cash balance of $36.7M","bullets":["Cash and cash equivalents estimated at $36.7 million as of June 30, 2026.","Preliminary unaudited data subject to completion of financial closing procedures.","No other financial results or guidance provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-323628","json":"https://secwatch.observer/filing/0001193125-26-323628.json","markdown":"https://secwatch.observer/filing/0001193125-26-323628.md","text":"https://secwatch.observer/filing/0001193125-26-323628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312526323628/0001193125-26-323628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312526323628/d158934d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:05:20.328318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}